|
[Related PubMed/MEDLINE]
Total Number of Papers: 96
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: 5ARI |
| Long Form |
: 5alpha-reductase inhibitor |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times? |
--- |
| 2 |
2022 |
5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care. |
CI |
| 3 |
2022 |
5alpha-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. |
BC, CI, HR |
| 4 |
2022 |
A Novel Nomogram Based on Initial Features to Predict BPH Progression. |
BPH, LUTS, PSA |
| 5 |
2022 |
Depression risk associated with the use of 5alpha-reductase inhibitors versus alpha-blockers: A retrospective cohort study in South Korea. |
AB, BPH, HR, PS |
| 6 |
2022 |
Inhibition of Human Prostate and Bladder Smooth Muscle Contraction, Vasoconstriction of Porcine Renal and Coronary Arteries, and Growth-Related Functions of Prostate Stromal Cells by Presumed Small Molecule Galphaq/11 Inhibitor, YM-254890. |
BPH, LUTS, OAB |
| 7 |
2022 |
Post-Finasteride Syndrome. Literature Review. |
BPH, PFS |
| 8 |
2022 |
Predictive factors for alpha blocker use after transurethral prostatectomy: Can preoperative urodynamic outcome predict alpha blocker medication after surgery? |
IPSS, OR, PSA, UDS |
| 9 |
2022 |
Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments. |
AB, CPRD |
| 10 |
2022 |
Risk Factors for Transurethral Coagulation for Hemostasis During Holmium Laser Enucleation of the Prostate. |
BPH, CI, HoLEP, ORs, PSA, TPV, TUC, TZV |
| 11 |
2021 |
5alpha-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis. |
ARR, SARS-CoV-2 |
| 12 |
2021 |
A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. |
ADT, AR, HRQoL, LHRH, oADT, PCa, RT, SOC |
| 13 |
2021 |
Potentially Inappropriate Prescribing for Prostatic Hyperplasia in Older Persons. |
BPH, EAU, SmPC |
| 14 |
2021 |
Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain. |
BPH, LUTS |
| 15 |
2021 |
The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: A population-based study. |
AB, BPH, CI, DM, HR |
| 16 |
2021 |
The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. |
PDE5, PRISMA, PSA, RCTs, SMD, TPV, TZV |
| 17 |
2021 |
The impact of preoperative lower urinary tract symptoms medication on the functional performance of holmium laser enucleation of the prostate. |
BPO, HoLEP, LUTS, PVR, QoL |
| 18 |
2021 |
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms. |
BPH, GPCRs, I-BPH, LUTS, MTOPS, PG, S-BPH, TZ |
| 19 |
2020 |
5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. |
5-AR, AGA, DHT |
| 20 |
2020 |
Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. |
AEs, IPPS, LUTS/BPH, PSA, PV, PVR, RCTs, SMD, voiding IPSS |
| 21 |
2020 |
Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date. |
FPHL |
| 22 |
2020 |
Macular Abnormalities Associated With 5alpha-Reductase Inhibitor. |
--- |
| 23 |
2020 |
National Trends in the Management of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. |
ABs, BPH, LUTSs, MISTs |
| 24 |
2020 |
Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. |
BPH, LUTS, PDE5i |
| 25 |
2020 |
Pharmacology of the lower urinary tract: update on LUTS treatment. |
AE, LUTS |
| 26 |
2020 |
Synthesis and Study of Some 17a-aza-D-homo Steroids as 5alpha-Reductase Inhibitors. |
--- |
| 27 |
2020 |
Ultrasound prostate parameters as predictors of successful trial without catheter after acute urinary retention in patients ongoing medical treatment for benign prostatic hyperplasia: a prospective multicenter study. |
ABs, AUR, BMI, BWT, TWOC |
| 28 |
2019 |
5-ARI induces autophagy of prostate epithelial cells through suppressing IGF-1 expression in prostate fibroblasts. |
BPH, IGF-1, LUTS |
| 29 |
2019 |
Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma. |
EEP, TZ-PCa |
| 30 |
2019 |
Association between 5alpha-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis. |
CIs, RR |
| 31 |
2019 |
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. |
BTA, CI, MD, NIH-CPSI, QoE, RR, TCM |
| 32 |
2019 |
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. |
AB, AE, BPH, BPHII, CENTRAL, CI, MD, NIH, PDEI, RCT, RR, WHO |
| 33 |
2019 |
Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicenter study. |
--- |
| 34 |
2019 |
The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging. |
CI, csPCa, mpMRI, MRI, OR, PCa, TRUS |
| 35 |
2018 |
Computer vision detects subtle histological effects of dutasteride on benign prostate. |
CI |
| 36 |
2018 |
Deregulation of ATG9A by impaired AR signaling induces autophagy in prostate stromal fibroblasts and promotes BPH progression. |
AR, BPH |
| 37 |
2018 |
Prostate-Specific Antigen Kinetics Following 5alpha-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy. |
PSA |
| 38 |
2018 |
Use of 5alpha-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study. |
BPH, CI |
| 39 |
2017 |
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). |
BPH, FDC, LUTS, MSHQ, SE |
| 40 |
2017 |
Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist. |
--- |
| 41 |
2017 |
Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. |
--- |
| 42 |
2017 |
Optimising patient outcomes with photoselective vaporization of the prostate (PVP): a review. |
BPH, LUTS, PVP, TURP |
| 43 |
2017 |
Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5alpha-reductase inhibitors. |
AS, PCA3 |
| 44 |
2017 |
Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-alpha-reductase inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a specific region in France. |
BPH, PCa |
| 45 |
2017 |
Re: Impact of Combination Therapy 5-Alpha Reductase Inhibitors (5-ARI) plus Alpha-Blockers (AB) on Erectile Dysfunction and Decrease of Libido in Patients with LUTS/BPH: A Systematic Review with Meta-Analysis. |
AB |
| 46 |
2017 |
The Genomic Alterations of 5alpha-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer. |
5-AR, UBC |
| 47 |
2017 |
Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. |
GnRH, LHRH, PAI |
| 48 |
2016 |
Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. |
AB, BPO, ED, LA, LUTS, RCT |
| 49 |
2016 |
NF-kappaB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. |
AR, AR-V7, AUASS, BPH, LUTS, TRUS |
| 50 |
2016 |
Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States. |
--- |
| 51 |
2015 |
5-alpha reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. |
BPH, CI, HR, TURP |
| 52 |
2015 |
Combination of 5alpha-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB. |
CAB |
| 53 |
2015 |
NF-kappaB and androgen receptor variant expression correlate with human BPH progression. |
AR-FL, AR-V, AR-V7, BPH, NF-kappaB |
| 54 |
2015 |
Patient's and physician's behavior on the management of benign prostatic hyperplasia among the patients at the risk of clinical progression. A multicenter noninterventional trial in Slovakia by "Prostate and Expectations of Treatment: Epidemiology Research" (PETER) study group. |
LUTS, PETER, RP |
| 55 |
2015 |
Risk of Fractures and Falls during and after 5-alpha Reductase Inhibitor Use: A Nationwide Cohort Study. |
HR |
| 56 |
2015 |
[Effect and safety of GreenLight HPS 120-W laser vaporization of the prostate for different benign prostatic hyperplasia populations]. |
AUR, PV, PVP, TURP |
| 57 |
2014 |
Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. |
CIs, OR, ORs, PCa |
| 58 |
2014 |
Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations. |
AUR, BPH, HPS, PVP, TURP |
| 59 |
2014 |
Long-term use of 5alpha-reductase inhibitors and the risk of male breast cancer. |
--- |
| 60 |
2014 |
Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5alpha-reductase inhibitors. |
DHT, PCa, pre-RC |
| 61 |
2014 |
Short-term pretreatment with a dual 5alpha-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. |
B-TURP, CD34, DHT, Hb, Ht, MVD, PSA, VEGF |
| 62 |
2014 |
Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. |
BPH/LUTS |
| 63 |
2013 |
5alpha-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. |
ADT, IADT |
| 64 |
2013 |
Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5alpha-reductase inhibitors. |
PCa |
| 65 |
2013 |
Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. |
BPH, LUTS |
| 66 |
2013 |
Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5alpha-reductase inhibitor therapy and alpha-blocker therapy: a retrospective analysis. |
AB, AUR, BPH, PSA |
| 67 |
2013 |
Medical management of lower urinary tract symptoms in men with benign prostatic enlargement. |
LUTS, PSA |
| 68 |
2013 |
Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5alpha-reductase inhibitors. |
AUC, PCa, PSA, PSAD, PZ, ROC, TZ |
| 69 |
2013 |
Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study. |
TPV, TURP |
| 70 |
2013 |
Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. |
AEs, ED, EjD |
| 71 |
2013 |
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. |
LUTS |
| 72 |
2013 |
Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. |
--- |
| 73 |
2013 |
Use of 5alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. |
--- |
| 74 |
2012 |
alpha-blocker monotherapy and alpha-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results. |
alpha-blocker, AUR, BPH, PSA, PV |
| 75 |
2012 |
Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. |
5ARIs, AS, CI, HR |
| 76 |
2012 |
Endocrine prevention and treatment of prostate cancer. |
DHT |
| 77 |
2011 |
Association of 5alpha-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy. |
PCa |
| 78 |
2011 |
Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory? |
--- |
| 79 |
2011 |
Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. |
BPH, IPSS, LUTS |
| 80 |
2011 |
Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. |
AEs, BPH, EF |
| 81 |
2011 |
Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. |
BPH |
| 82 |
2011 |
Risk stratification for benign prostatic hyperplasia (BPH) treatment. |
BPH |
| 83 |
2010 |
Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia. |
alpha-blocker, BPH, IPSS, PSA, PVR, ROC, TURP |
| 84 |
2010 |
Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. |
PCa, PSA |
| 85 |
2010 |
The influence of family history on prostate cancer risk: implications for clinical management. |
--- |
| 86 |
2009 |
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. |
CRPC, DHT, TARP |
| 87 |
2008 |
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. |
--- |
| 88 |
2008 |
Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm. |
BPH, LUTS, PSA, TURP |
| 89 |
2008 |
Management of symptomatic benign prostatic hyperplasia--today. |
BPH, IPSS, LUTS, PSA |
| 90 |
2007 |
Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. |
BPH, DHT, Hb, MVD, TURP |
| 91 |
2007 |
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. |
PSA, QoL, REDEEM |
| 92 |
2007 |
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. |
BPH, PROBE, PSA |
| 93 |
2007 |
[Benign prostate hyperplasia: success and limitations of pharmacological therapy]. |
BPH |
| 94 |
2006 |
[Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate]. |
BPH, TURP |
| 95 |
2005 |
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. |
PCPT |
| 96 |
2003 |
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. |
DT36 |
|
A Search Service for Abbreviation / Long Form
